Opinion|Videos|February 21, 2025
Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL
Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Advertisement
Episodes in this series
- How do patient-reported outcomes and real-world evidence influence your clinical decision-making process when selecting BTK inhibitor therapies for CLL and MCL?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
3
ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM
4
Early Secukinumab Sustains Psoriasis Clearance a Year After Stopping
5